Cyclosporin A and tacrolimus reduce T‐cell polyfunctionality but not interferon‐γ responses directed at cytomegalovirus

Cytomegalovirus (CMV) ‐specific immunity is often estimated by the number of in vitro CMV antigen‐inducible interferon‐γ‐positive (IFN‐γ+) T cells. However, recent work indicates that simultaneous production of IFN‐γ, tumour necrosis factor‐α (TNF‐α) and interleukin‐2 (IL‐2) (referred to as ‘polyfunctionality’) is more relevant for anti‐viral protection. Here, we compared polyfunctionality of CMV‐specific T cells (pp65 and IE‐1 proteins) in 23 solid‐organ transplant patients and seven healthy controls by flow cytometry. The proportions of TNF‐α+/IFN‐γ+/IL‐2 cells among the activated cells were significantly reduced in transplant patients but not the frequencies of IFN‐γ+ CD8+ T cells. Immunosuppression reduces polyfunctionality, which reflects the increased infection risk in this patient group.

[1]  M. Boeckh,et al.  Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. , 2010, Blood.

[2]  E. Arbustini,et al.  Preemptive Therapy for Systemic and Pulmonary Human Cytomegalovirus Infection in Lung Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  F. Kern,et al.  T cell response to the cytomegalovirus major capsid protein (UL86) is dominated by helper cells with a large polyfunctional component and diverse epitope recognition. , 2008, The Journal of infectious diseases.

[4]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[5]  C. Gray,et al.  Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development , 2006, Expert review of vaccines.

[6]  M. Heemskerk,et al.  Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. , 2006, Blood.

[7]  M. Roederer,et al.  Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. , 2005, Trends in immunology.

[8]  C. Craddock,et al.  Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers , 2005, The Journal of experimental medicine.

[9]  F. Pereyra,et al.  Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients , 2004, Current opinion in infectious diseases.

[10]  R. Koup,et al.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know , 2004, Nature Medicine.

[11]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[12]  L. Picker,et al.  Mapping T cell epitopes by flow cytometry. , 2003, Methods.

[13]  G. Cathomas,et al.  Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. , 1999, The Journal of infectious diseases.

[14]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.